INT184063

From wiki-pain
Revision as of 05:07, 21 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.69
First Reported 2005
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 17
Total Number 17
Disease Relevance 10.97
Pain Relevance 2.37

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (Jak2) cytosol (Jak2) signal transduction (Jak2)
histone binding (Jak2) cytoskeleton (Jak2) nucleus (Jak2)
Anatomy Link Frequency
Th17 cells 1
NK cells 1
astrocytes 1
spleen 1
Jak2 (Mus musculus)
Jak2 - V617F (4)
Pain Link Frequency Relevance Heat
COX-2 inhibitor 2 98.60 Very High Very High Very High
cytokine 215 93.36 High High
Hippocampus 36 92.52 High High
cINOD 63 89.52 High High
Inflammation 254 87.92 High High
Central nervous system 64 86.56 High High
chemokine 9 77.84 Quite High
rheumatoid arthritis 21 71.24 Quite High
Pain 5 70.72 Quite High
fibrosis 32 69.88 Quite High
Disease Link Frequency Relevance Heat
Erythrocytosis 171 100.00 Very High Very High Very High
Myelodysplastic Syndromes 372 99.88 Very High Very High Very High
Splenomegaly 32 99.20 Very High Very High Very High
Malignant Neoplastic Disease 11 98.88 Very High Very High Very High
B-cell Lymphoma 2 96.68 Very High Very High Very High
Leukemia 34 96.48 Very High Very High Very High
Disease 468 95.32 Very High Very High Very High
Cancer 195 94.32 High High
Myelofibrosis 108 93.12 High High
Targeted Disruption 128 93.04 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Constitutive activation of JAK2 V617F and downstream signaling pathways in polycythemic mice
Positive_regulation (activation) of JAK2 V617F (V617F)
1) Confidence 0.69 Published 2006 Journal PLoS ONE Section Body Doc Link PMC1762384 Disease Relevance 0.11 Pain Relevance 0.03
There was constitutive activation of JAK2 V617F in BM and spleen cells, as evidenced by phosphorylation at the activation loop tyrosines 1007 and 1008, whereas JAK2 WT was not detectably phosphorylated.
Positive_regulation (activation) of JAK2 V617F (V617F) in spleen
2) Confidence 0.69 Published 2006 Journal PLoS ONE Section Body Doc Link PMC1762384 Disease Relevance 0 Pain Relevance 0
Although this is the first report to demonstrate a JAK alteration in COX-/- mice, COX-2 inhibitors have been shown to dampen interleukin-12 signaling by inhibiting the activation of JAK2 [38].
Positive_regulation (activation) of JAK2 associated with cox-2 inhibitor
3) Confidence 0.53 Published 2007 Journal Genome Biol Section Body Doc Link PMC1839133 Disease Relevance 0.26 Pain Relevance 0.35
JAK2 V617F-induced polycythemia is independent of Src kinases
Neg (independent) Positive_regulation (independent) of JAK2 V617F (V617F) associated with erythrocytosis
4) Confidence 0.50 Published 2006 Journal PLoS ONE Section Body Doc Link PMC1762384 Disease Relevance 1.49 Pain Relevance 0.03
In polycythemia vera (PV), an activating mutation in Janus kinase 2 (JAK2V617) induces splenomegaly and an increase in hematocrit.
Positive_regulation (activating) of Janus kinase 2 associated with splenomegaly and myelodysplastic syndromes
5) Confidence 0.48 Published 2009 Journal PLoS ONE Section Abstract Doc Link PMC2749451 Disease Relevance 0.95 Pain Relevance 0
However, the fa</span>cts that polycythemia induced in mice by JAK2 V617F is polyclonal and manifested immediately following engraftment argue that JAK2 V617F is both necessary and sufficient for this phenotype.
Positive_regulation (sufficient) of JAK2 V617F (V617F) associated with erythrocytosis
6) Confidence 0.46 Published 2006 Journal PLoS ONE Section Body Doc Link PMC1762384 Disease Relevance 0.91 Pain Relevance 0.06
Attempts to correlate clinical response to imatinib in PV patients to objective molecular improvements in JAK2V617F burden showed only modest decreases in mutation levels even in those patients with the most robust response (Jones et al 2005; Hyjek et al 2006).
Positive_regulation (improvements) of JAK2V617F associated with myelodysplastic syndromes
7) Confidence 0.42 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721304 Disease Relevance 1.03 Pain Relevance 0.10
The differentiation of Th17 cells depends on the activation of janus kinase 2 (JAK2), signal transducer and activator of transcription 3 (STAT3) and the transcription factor RAR-related organ receptor C2 (RORC2) and is regulated by a combination of cytokines, including IL-6, IL-1B (IL-1?)
Positive_regulation (activation) of JAK2 in Th17 cells associated with cytokine
8) Confidence 0.39 Published 2010 Journal BMC Immunol Section Body Doc Link PMC3016394 Disease Relevance 0.38 Pain Relevance 0.31
-mediated activation of JAK2 and ERK1/2, STAT1 binds to BACE1 promoter region to increase BACE1 protein expression in astrocytes [91].
Positive_regulation (activation) of JAK2 in astrocytes
9) Confidence 0.39 Published 2008 Journal J Neuroinflammation Section Body Doc Link PMC2442055 Disease Relevance 0.77 Pain Relevance 0.39
uses JAK1 and JAK2, which activate mainly STAT1, whereas IL-6 binding to the IL-6 receptor ?
Positive_regulation (uses) of JAK2
10) Confidence 0.31 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1174965 Disease Relevance 0.30 Pain Relevance 0.30
These mutations probably result in impaired JAK2 degradation and sustained JAK2 activation [94].
Positive_regulation (activation) of JAK2
11) Confidence 0.29 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1174965 Disease Relevance 1.44 Pain Relevance 0.04
activated JAK2 and ERK1/2.
Positive_regulation (activated) of JAK2
12) Confidence 0.26 Published 2007 Journal Mol Neurodegener Section Body Doc Link PMC2211305 Disease Relevance 0.53 Pain Relevance 0.18
activated JAK2 and ERK1/2.
Positive_regulation (activated) of JAK2
13) Confidence 0.26 Published 2007 Journal Current Genomics Section Body Doc Link PMC2647160 Disease Relevance 1.17 Pain Relevance 0.22
activation of Jak2, Tyk2, Stat3, and Stat4 in T and NK cells [98, 99].
Positive_regulation (activation) of Jak2 in NK cells
14) Confidence 0.26 Published 2008 Journal PPAR Research Section Body Doc Link PMC2490815 Disease Relevance 0.47 Pain Relevance 0.24
Phosphatidylinositol 3-kinase (PI3K), its effector kinase Akt, JAK1, and JAK2 are all required for phosphorylation of both serine 727 and tyrosine 701 of STAT1 [62].
Positive_regulation (required) of JAK2
15) Confidence 0.25 Published 2008 Journal J Neuroinflammation Section Body Doc Link PMC2569027 Disease Relevance 0.13 Pain Relevance 0.03
One major effect of the JAK2 activation by Bcr-Abl is the increase in c-Myc expression (Xie et al 2002) which is important for leukemia induction (Sawyers et al 1992).
Positive_regulation (activation) of JAK2 associated with leukemia
16) Confidence 0.21 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2503652 Disease Relevance 0.53 Pain Relevance 0
Engagement of gp130 triggers activation of the associated Janus kinases Jak1, Jak2 and Tyk2 [28,29] and subsequent tyrosine phosphorylation of gp130.
Positive_regulation (activation) of Jak2
17) Confidence 0.11 Published 2010 Journal Cell Div Section Body Doc Link PMC2887830 Disease Relevance 0.52 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox